YOLFTbeta
SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation

ICU · NASDAQ · Healthcare / Biotechnology

0.8384USD-0.21 (-20.15%)

Price History

Full chart

Market Stats

Previous Close1.05
Open1.08
Day Range0.8051 – 1.08
52-Week Range2.07 – 7.35
Volume593.82K
Market Cap15.07M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.89
Dividend Yield0.00%
Beta-1.03
50-Day Avg3.33
200-Day Avg3.27

About

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Eric Schlorff
  • Employees18
  • Headquarters3513 Brighton Boulevard, Denver, CO, United States, 80216, USA
  • Websitehttps://seastarmedical.com

Leadership

  • Mr. Eric SchlorffCEO, Treasurer, President & Executive Director · b. 1973
  • Mr. Michael Messinger CPAChief Financial Officer · b. 1975
  • Colonel Kevin Chung FACP, M.D.Chief Medical Officer · b. 1973
  • Dr. H. David Humes M.D.Co-Founder & Scientific Advisor
  • Mr. Tom MullenVice President of Operations & Product Development
  • Mr. Bradford K. Towne CPAController & Principal Accounting Officer · b. 1978
  • Mr. Tim VaracekSenior Vice President of Commercial & Business Operations
  • Mr. Sai P. Iyer Ph.D.Senior Vice President of Medical Affairs & Research

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000135.00K1.23M
Growth (%)-----+814.07%
Cost of Revenue---0053.00K
Gross Profit---0135.00K1.18M
Gross Margin----100.00%95.71%
Operating Expense---14.21M17.98M13.36M
Operating Income-6.45M-4.45M-11.61M-14.21M-17.84M-12.18M
Operating Margin-----13216.30%-986.63%
EBITDA-5.24K-4.38M-11.61M-11.14M-24.58M-12.16M
EBITDA Margin-----18209.63%-985.17%
Net Income-3.28M-4.60M-23.01M-26.23M-24.83M-12.15M
Net Income Margin-----18392.59%-984.60%
R&D4.03M2.77M2.82M5.97M9.11M7.52M
R&D as % of Total Revenue----6744.44%609.24%
Interest Expense3.31M212.00K630.00K1.08M244.00K329.00K
Interest Expense % of Total Revenue----180.74%26.66%

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.91M603.00K3.04M3.51M4.66M14.16M
Total Liabilities74.49M3.42M23.80M17.38M6.84M3.74M
Total Equity-71.58M-2.82M-20.76M-13.87M-2.18M10.42M
Cash2.81M510.00K47.00K176.00K1.82M11.98M
Total Debt83.00K2.62M8.83M9.08M574.00K525.00K
Net Debt-2.72M2.11M8.78M8.90M-1.25M-11.46M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-5.57M-5.11M-7.79M-10.29M-16.01M-13.60M
Investing Cash Flow--105.57M----
Financing Cash Flow4.89M2.82M7.33M10.41M17.65M23.76M
Capital Expenditure500000
Free Cash Flow-5.57M-5.11M-7.79M-10.29M-16.01M-13.60M
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateMay 24, 2021Aug 16, 2021Nov 17, 2021Dec 31, 2021Apr 6, 2022Aug 16, 2022Nov 14, 2022Mar 30, 2023May 15, 2023Aug 14, 2023Nov 14, 2023Mar 13, 2024May 14, 2024Aug 13, 2024Nov 13, 2024Mar 27, 2025May 14, 2025Aug 13, 2025Nov 13, 2025Mar 26, 2026May 13, 2026Aug 12, 2026Nov 12, 2026
EPS Estimate---------50.00-62.50-62.50-0.13-37.50-14.10-11.30-0.18-5.20-4.30-1.50-1.01-0.82-0.91-0.95
EPS Actual0.18-0.150.022.220.010.01-0.05-2.04-100.00-62.50-92.50-0.22-47.50-10.30-11.00-0.90-4.40-1.80-1.30-0.80-0.90-0.91-
Surprise---------100.00%0.00%-48.00%-69.23%-26.67%26.95%2.65%-400.00%15.38%58.14%13.33%21.18%-9.76%0.00%-
Timing-----After-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap15.07M
Enterprise Value8.77M
Trailing P/E0.00
Forward P/E0.00
Price / Sales8.80
Price / Book3.63
EPS-1.89
Book Value1.01
Revenue (TTM)1.71M
Gross Profit (TTM)1.59M
Profit Margin0.00%
Operating Margin-616.42%
Return on Equity-356.87%
Return on Assets-102.67%
Shares Outstanding4.41M
Shares Float4.36M
Beta-1.03
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 10.00
  • Buy
    1

Ownership Breakdown

Institutions
7.62%
Insiders
11.62%
Retail / Other
80.76%

Top Institutional Holders

  • Geode Capital Management, LLC
    55.64K1.26%
  • Vanguard Capital Management, LLC
    28.79K0.65%
  • Jane Street Group LLC
    27.96K0.63%
  • Vanguard Fiduciary Trust Co
    13.69K0.31%
  • PNC Financial Services Group Inc
    1.75K0.04%
  • Tower Research Capital LLC
    1.40K0.03%
  • BlackRock Inc
    9130.02%
  • UBS Group AG
    7930.02%
  • Advisor Group Holdings, Inc.
    2300.01%
  • Goss Wealth Management LLC
    1760.00%
  • Vanguard Global Advisers, LLC
    1650.00%
  • TD Waterhouse Canada Inc
    220.00%
  • Morgan Stanley - Brokerage Accounts
    200.00%

Top Fund Holders

  • Fidelity Extended Market Index
    20.68K0.47%
  • Abante Quant Value FI
    11.36K0.26%
  • Fidelity Total Market Index
    8.66K0.20%
  • Fidelity Nasdaq Composite Index
    7.16K0.16%
  • Fidelity Series Total Market Index
    5.81K0.13%
  • Dimensional US Core Equity 2 ETF
    2.83K0.06%
  • Vanguard U.S. Eq Idx £ Acc
    1650.00%

Stock Splits

  • Jan 5, 20261:10
  • Jun 10, 20241:25